April 11, 2026
Myelin oligodendrocyte glycoprotein (MOG)-associated disease (MOGAD) is a rare antibody-mediated inflammatory demyelinating disorder of the central nervous system. The phenotypic overlap between MOGAD and related diseases can hinder clear diagnostic separation and delay targeted treatment.
"Because MOGAD is a distinct condition with a different immune system pathology, accurate diagnosis is essential for patients in terms of prognosis and management," says John J. Chen, M.D., Ph.D., a neuro-ophthalmologist at Mayo Clinic in Rochester, Minnesota.
Symptoms of MOGAD include vision loss, eye pain, muscle weakness, confusion, seizures, and headaches — which can resemble related disorders such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder.
"MOG antibody-associated disease can often be differentiated from MS by the absence of scar formation and the tendency of lesions to resolve," says Eoin P. Flanagan, M.B., B.Ch., a neurologist at Mayo Clinic in Rochester, Minnesota. "High-positive MOG antibody levels in the blood are strongly indicative of MOGAD, but spinal fluid testing can be useful in uncertain cases."
Mayo Clinic offers the first coordinated, multidisciplinary clinic in the world that is devoted specifically to MOGAD. Patients receive a comprehensive assessment including:
- Standard ophthalmic testing. Tests include visual acuity, pupillary exam, visual fields and optical coherence tomography (OCT).
- Neuroimaging. MRI of the orbits and brain assesses optic nerve inflammation and looks for brain lesions suggestive of alternative diagnoses such as MS.
- Serological testing. Blood testing looks for antibodies to aquaporin-4 (AQP4) and MOG unless the presentation is classic for MS-associated optic neuritis.
- Cerebrospinal fluid (CSF) studies: Lumbar puncture may be considered to evaluate for oligoclonal bands supporting an MS diagnosis. CSF testing for MOG antibodies can identify an additional subset (~10%) of patients with MOGAD who are seronegative in blood.
Mayo researchers originally discovered the AQP4 antibody in 2004, and Mayo Clinic was the first center in the United States to offer clinical MOG antibody testing — providing institutional expertise in antibody-mediated demyelinating disorders.
"Early availability of the live cell–based MOG assay at Mayo Clinic, before it was widely accessible in the U.S., resulted in an unparallelled cohort of clinical samples and biospecimens," Dr. Chen says. "This has enabled foundational insights into the clinical spectrum, imaging features and outcomes of MOGAD."
Patients are typically treated initially with high-dose intravenous corticosteroids. When they have severe optic neuritis or inadequate response to steroids, plasma exchange is frequently offered. Plasma exchange is an escalation therapy that removes circulating pathogenic antibodies and has been shown to improve outcomes in severe inflammatory attacks.
"Timing is critical," Dr. Chen says. "Early treatment, especially prompt corticosteroids and timely escalation to plasma exchange in severe cases, can significantly influence visual outcomes. Rapid referral is particularly important for patients with profound vision loss, bilateral involvement, poor steroid response, or atypical imaging features."
Mayo Clinic's collaborative network regarding MOGAD extends nationally and internationally to accelerate discovery and harmonize clinical approaches. Current research efforts include:
- Participation in industry-sponsored, randomized clinical trials for relapsing MOGAD.
- A multicenter, PCORI-funded randomized trial (TIMELY PLEX) evaluating early versus rescue plasma exchange for severe optic neuritis and transverse myelitis. This trial spans multiple U.S. sites and has the potential to change standards for acute escalation therapy.
- Ongoing translational studies focused on disease pathogenesis including cytokine and complement biology, and advanced imaging biomarkers such as OCT angiography and ultra-high-field 7T MRI.
As a tertiary referral center for complex and treatment-refractory optic neuritis and MOGAD, Mayo Clinic offers multidisciplinary expertise, advanced imaging, gold-standard antibody testing, research and participation in cutting-edge clinical trials.
"Optic neuritis is no longer a single disease entity," Dr. Chen says. "Early, accurate phenotyping has important implications for prognosis and treatment. Early identification and referral of these disorders can prevent misdiagnosis, and allow for timely therapeutic intervention, and consideration of clinical trial enrollment — all of which can meaningfully improve patient outcomes."
For more information
Refer a patient to Mayo Clinic.